Huang Peng, Liu Hong, Liu Zhenxiu, Huang Liqun, Lu Min, Wang Lina, Yu Yaqiong, Jin Xiaohong
Department of Anesthesiology and Pain, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Acta Neurochir (Wien). 2023 Dec;165(12):3905-3912. doi: 10.1007/s00701-023-05823-z. Epub 2023 Oct 28.
To evaluate the effectiveness of percutaneous balloon compression (PBC) in treating trigeminal neuralgia (TN) and determine improvements in quality of life (QoL) and daily functional status.
Data from primary TN (pTN) patients treated with PBC from December 2018 to April 2021 were retrospectively analyzed. Short-Form 36 (SF-36) Health Survey and Functional Independence Measure (FIM) assessments were used to evaluate patients' QoL and physical function every 6 months after surgery, and facial pain was evaluated every 3 to 6 months post-surgery.
A total of 80 pTN patients were enrolled for analysis. The Barrow Neurological Institute (BNI) scores of I-II were achieved in 67 (83.8%) patients immediately after the surgery. The estimated rates of BNI I-II pain relief at one, two, and three years were 94.2%, 87.6%, and 83.2%, respectively. All aspects of the SF-36 questionnaire were significantly improved after the PBC, especially in terms of role physical (RP), bodily pain (BP), and social functioning (SF). Patients' functional outcomes measured by FIM at the 6-month follow-up examination were 108.6 ± 9.9, which was significantly improved compared with the pretreatment scores (90.8 ± 12.7). There was no difference between the severity of facial numbness in FIM and any item of the SF-36 except RP (P = 0.004) at 6 months after surgery. There was also no difference in SF-36 and FIM between patients with or without facial hyperalgesia.
PBC can produce long-term and stable pain relief and significantly improve the patient's QoL and physical function. However, further well-designed, high-level, evidence-based studies are needed to precisely assess the efficacy of PBC for pTN patients.
评估经皮球囊压迫术(PBC)治疗三叉神经痛(TN)的有效性,并确定生活质量(QoL)和日常功能状态的改善情况。
回顾性分析2018年12月至2021年4月接受PBC治疗的原发性TN(pTN)患者的数据。采用简明健康调查问卷(SF-36)和功能独立性测量(FIM)评估,在术后每6个月评估患者的生活质量和身体功能,术后每3至6个月评估面部疼痛情况。
共纳入80例pTN患者进行分析。术后立即有67例(83.8%)患者达到巴罗神经学研究所(BNI)I-II级评分。术后1年、2年和3年BNI I-II级疼痛缓解的估计率分别为94.2%、87.6%和83.2%。PBC术后SF-36问卷的所有方面均有显著改善,尤其是在躯体角色(RP)、身体疼痛(BP)和社会功能(SF)方面。在6个月随访检查时,通过FIM测量的患者功能结局为108.6±9.9,与治疗前评分(90.8±12.7)相比有显著改善。术后6个月时,FIM中面部麻木的严重程度与SF-36中除RP外的任何项目之间无差异(P = 0.004)。有或无面部痛觉过敏的患者在SF-36和FIM方面也无差异。
PBC可产生长期稳定的疼痛缓解,并显著改善患者的生活质量和身体功能。然而,需要进一步设计良好、高水平、基于证据的研究来精确评估PBC对pTN患者的疗效。